Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

231

Citations

18

References

2016

Year

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T. Heffner,

The Lancet Oncology

Open-label SubstudyImmunologyClinical TrialsRituximab-refractory WaldenströmImmunotherapyMedicinePhase 3

References

	Year	Citations

Page 1